The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Continuous versus Intermittent Infusion of Vancomycin in Severe Staphylococcal Infections: Prospective Multicenter Randomized Study
Open accessAbstract
A continuous infusion of vancomycin (CIV) may provide an alternative mode of infusion in severe hospital-acquired methicillin-resistant staphylococcal (MRS) infections. A multicenter, prospective, randomized study was designed to compare CIV (targeted plateau drug serum concentrations of 20 to 25 mg/liter) and intermittent infusions of vancomycin (IIV; targeted trough drug serum concentrations of 10 to 15 mg/liter) in 119 critically ill patients with MRS infections (bacteremic infections, 35%; pneumonia, 45%). Microbiological and clinical outcomes, safety, pharmacokinetics, ease of treatment adjustment, and cost were compared. Microbiological and clinical outcomes and safety were similar. CIV patients reached the targeted concentrations faster (36 ± 31 versus 51 ± 39 h, P = 0.029) and fewer samples were required for treatment monitoring than with IIV patients (7.7 ± 2.2 versus 11.8 ± 3.9 per treatment, P < 0.0001). The variability between patients in both the area under the serum concentration-time curve (AUC 24h ) and the daily dose given over 10 days of treatment was lower with CIV than with IIV (variances, 14,621 versus 53,975 mg 2 /liter 2 /h 2 [ P = 0.026] and 414 versus 818 g 2 [ P = 0.057], respectively). The 10-day treatment cost per patient was $454 ± 137 in the IIV group and was 23% lower in the CIV group ($321 ± 81: P < 0.0001). In summary, for comparable efficacy and tolerance, CIV may be a cost-effective alternative to IIV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
CDC definitions for nosocomial infections, 1988
Garner, J. S., Jarvis, W. R., Emori, T. G., Horan, T. C., & Hughes, J. M. (1988) · American Journal of Infection Control · doi:10.1016/0196-6553(88)90053-3 · Cited by 5,672
CDC definitions for nosocomial infections
Yangco, B. G. (1989) · American Journal of Infection Control · doi:10.1016/s0196-6553(89)80013-6 · Cited by 3,770
A simplified acute physiology score for ICU patients
GALL, J.-R. L., LOIRAT, P., ALPEROVITCH, A., GLASER, P., GRANTHIL, C., MATHIEU, D., MERCIER, P., THOMAS, R., & VILLERS, D. (1984) · Critical Care Medicine · doi:10.1097/00003246-198411000-00012 · Cited by 1,251
Prognosis in Acute Organ-System Failure
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Annals of Surgery · doi:10.1097/00000658-198512000-00004 · Cited by 1,225
Levine, D. P., Fromm, B. S., & Reddy, B. R. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-9-674 · Cited by 577
Fridkin, S. K., Steward, C. D., Edwards, J. R., Pryor, E. R., McGowan, Jr., Archibald, L. K., Gaynes, R. P., & Tenover, F. C. (1999) · Clinical Infectious Diseases · doi:10.1086/520193 · Cited by 486
Nephrotoxicity of vancomycin, alone and with an aminoglycoside
Rybak, M. J., Albrecht, L. M., Boike, S. C., & Chandrasekar, P. H. (1990) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/25.4.679 · Cited by 388
Lamer, C., de Beco, V, Soler, P., Calvat, S., Fagon, J. Y., Dombret, M. C., Farinotti, R., Chastre, J., & Gibert, C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.2.281 · Cited by 297
Penetration of vancomycin into human lung tissue
Cruciani, M., Gatti, G., Lazzarini, L., Furlan, G., Broccali, G., Malena, M., Franchini, C., & Concia, E. (1996) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/38.5.865 · Cited by 264
[Antibiogram Committee of the French Microbiology Society. Report 2000-2001].
Cj, S., Carret, G., Cavallo, J.-D., et al. (2000) · PubMed · Cited by 190
Pharmacokinetics of vancomycin
Moellering, R. C. (1984) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/14.suppl_d.43 · Cited by 178
James, J. K., Palmer, S. M., Levine, D. P., & Rybak, M. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.3.696 · Cited by 143
COOK, F. V., & FARRAR, W. E. (1978) · Annals of Internal Medicine · doi:10.7326/0003-4819-88-6-813 · Cited by 143
Elting, L. S., Rubenstein, E. B., Kurtin, D., Rolston, K. V. I., Fangtang, J. T., Martin, C. G., RAAD, I. I., Whimbey, E. E., Manzullo, E. F., & Bodey, G. P. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2597::aid-cncr27>3.0.co;2-l · Cited by 109
Why monitor peak vancomycin concentrations?
Saunders, N. J. S. G. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92890-8 · Cited by 92
Outcome Assessment of Minimizing Vancomycin Monitoring and Dosing Adjustments
Karam, C. M., McKinnon, P. S., Neuhauser, M. M., & Rybak, M. J. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.4.257.30933 · Cited by 75
The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis
Leder, K. S., Turnidge, J. D., Korman, T. M., & Grayson, M. L. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.1.113 · Cited by 68
A Closer Look at Vancomycin, Teicoplanin, and Antimicrobial Resistance
Zeckel, M. L. (1997) · Journal of Chemotherapy · doi:10.1179/joc.1997.9.5.311 · Cited by 23
Cited by
Barlam, T. F., Cosgrove, S. E., Abbo, L. M., MacDougall, C., Schuetz, A. N., Septimus, E. J., Srinivasan, A., Dellit, T. H., Falck-Ytter, Y. T., Fishman, N. O., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw118 · Cited by 3,061
Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
Rybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., Mueller, B. A., Pai, M. P., Wong-Beringer, A., Rotschafer, J. C., et al. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa036 · Cited by 1,202
Roberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., Hope, W. W., Farkas, A., Neely, M. N., Schentag, J. J., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70036-2 · Cited by 1,046
Pharmacokinetic issues for antibiotics in the critically ill patient
Roberts, J. A., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181961bff · Cited by 862
Metadata
- Authors
- Wysocki, M., Delatour, F., Faurisson, F., Rauss, A., Pean, Y., Misset, B., Thomas, F., Timsit, J.-F., Similowski, T., Mentec, H., Mier, L., Dreyfuss, D., & The Study Group
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2001-09
- Volume
- 45
- Issue
- 9
- Pages
- 2460-2467
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2104779095
- Cited by
- 385
- References
- 19
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.